The vocabulary around non-invasive positive-pressure therapy is cluttered. CPAP, APAP, BiPAP, BiPAP-S, BiPAP-ST, AVAPS, iVAPS, ASV, home NIV, home ventilator — these labels refer to overlapping categories that a physician chooses between based on the specific clinical picture in front of them. For a patient or family trying to understand which mode is appropriate, the label-first approach is backwards. The clinical picture selects the mode; the mode is then matched to a device.
This article lays out a decision tree for matching mode to clinical picture, starting from the questions a sleep physician actually asks and ending with the mode and device category.
The three questions that structure the decision
For any patient being considered for positive-pressure therapy:
- Is the airway the problem, or is the drive the problem, or is the muscle the problem? Airway (upper-airway collapse) → CPAP family. Drive (central events, Cheyne-Stokes) → BiPAP-ST or ASV territory. Muscle (NMD, chest wall restriction) → BiPAP-ST or TVAPS or home ventilator depending on severity.
- Is there hypercapnia at baseline? If yes, volume-assurance (TVAPS) or at minimum BiPAP-ST. If no and the picture is purely obstructive, CPAP.
- Are coexisting conditions ruling out specific modes? HFrEF with LVEF ≤ 45% rules out ASV. Severe bulbar weakness complicates mask choice. Certain medications (opioids, benzodiazepines) worsen central events.
The tree below flows from these questions.
Level 1 — CPAP / APAP
Clinical picture: obstructive sleep apnea, AHI ≥ 5 with symptoms or AHI ≥ 15 regardless of symptoms, no hypercapnia, no central predominance, no significant comorbid cardiopulmonary disease requiring non-CPAP mode.
How it works: a single continuous pressure maintains upper-airway patency throughout the breath cycle. Auto-titrating (APAP) variants adjust pressure within a clinician-set range based on detected events and flow-limitation signals.
When it is enough: the large majority of OSA. An AHI of 30, a BMI of 35, and symptoms of daytime somnolence in a middle-aged adult without hypercapnia → CPAP is the correct starting point.
When it is not enough: residual AHI remains elevated on CPAP despite mask fit and pressure optimisation; patient cannot tolerate high CPAP pressures (usually > 15 cmH₂O); hypercapnia is present; central events predominate or emerge on therapy.
Typical devices: ResMed AirSense 10, AirSense 11, AirStart 10; Philips DreamStation CPAP; BMC GII Auto; BPL Harmony Auto; Oxymed Auto CPAP. Price range ₹30,000–1,10,000.
Level 2 — BiPAP-S (bilevel, spontaneous)
Clinical picture: OSA patient who cannot tolerate the required CPAP pressure, particularly at prescribed levels above 15 cmH₂O. Also: mild to moderate overlap syndrome (COPD + OSA) where bilevel offers ventilatory support benefit.
How it works: two pressures — higher IPAP on inspiration, lower EPAP on expiration. The pressure support (IPAP − EPAP) reduces the work of breathing; the pressure difference itself often makes high pressures more tolerable than the same average pressure delivered as CPAP.
When it is enough: OSA patient struggling with CPAP pressure intolerance; mild overlap syndromes; some post-bariatric-surgery patients needing short-term bilevel support.
When it is not enough: central events predominate (no backup rate); hypercapnia is not controlled; neuromuscular progression is making spontaneous effort unreliable.
Typical devices: ResMed AirCurve 10 S, Philips DreamStation BiPAP Auto (without ST engaged), BMC Y30T (in S mode), Oxymed BiPAP i-Series P1. Price range ₹80,000–1,80,000.
Level 3 — BiPAP-ST (spontaneous-timed)
Clinical picture: central sleep apnea not responsive to CPAP in non-HFrEF patients; moderate neuromuscular disease; post-stroke central apnea; stable chronic hypercapnic COPD; severe kyphoscoliosis without extreme hypoventilation.
How it works: bilevel with a backup rate. The machine delivers machine-timed breaths if the patient fails to trigger within the backup-rate interval.
When it is enough: most indications above, where the patient can generate adequate volume on the set IPAP–EPAP pressure support.
When it is not enough: hypercapnia persists on BiPAP-ST; NMD progression requires escalating pressure support that is not being tracked by a fixed IPAP; overnight tidal volume is unstable with changing body position or sleep stage.
Typical devices: ResMed AirCurve 10 ST, Lumis 100 VPAP ST; Philips DreamStation BiPAP (with ST capability); BMC Y30T; Home Medix HM-BV-30; BPL LifePap 25 STa. Price range ₹1,00,000–2,50,000.
Level 4 — BiPAP with volume assurance (TVAPS, AVAPS, iVAPS)
Clinical picture: OHS with CPAP-non-responsive hypercapnia; moderate to advanced neuromuscular disease; central hypoventilation syndromes; stable severe COPD with chronic hypercapnia and recurrent hypercapnic exacerbations; kyphoscoliosis with significant restriction.
How it works: bilevel-ST with an added volume target. The device varies IPAP within a clinician-set range to hit a target tidal volume on each breath.
When it is enough: most of the Level 3 indications where the clinical picture is unstable enough that pressure targeting alone does not reliably produce adequate volume. The Pickwick trial established TVAPS non-inferiority to CPAP for long-term outcomes in OHS and superiority for CO₂ normalisation in non-severe-OSA OHS. (Masa JF et al, Pickwick trial (Lancet 2019))
When it is not enough: interface tolerance fails; secretion management becomes the limiting factor (bulbar ALS); the patient is becoming dependent on the device for a majority of the 24-hour cycle, which suggests escalation to a full home ventilator.
Typical devices: ResMed Lumis VPAP ST-A (iVAPS); Philips DreamStation BiPAP AVAPS; Home Medix HM-BV-30 (TVAPS mode); BMC G3 B30VT. Price range ₹1,40,000–3,00,000.
Level 5 — Home mechanical ventilation (traditional ventilator)
Clinical picture: advanced NMD with tracheostomy or ventilator-dependence > 16 hours per day; pediatric home ventilation in complex cases; high-support patients who have outgrown the BiPAP-ST/TVAPS mode capabilities.
How it works: full home ventilator with expanded mode options — pressure-control, volume-control, SIMV, PSV, multiple alarm tiers, dual external battery, higher maximum pressure ranges, more precise I-time and I:E control, often with tracheostomy circuit and active humidification.
When it is indicated: the main distinction from a TVAPS-capable BiPAP is dependence. A patient who uses non-invasive bilevel for 8 hours of sleep and is otherwise independent is on a BiPAP. A patient using ventilatory support for most of the 24-hour cycle, particularly via tracheostomy or in combination with daytime mouthpiece ventilation, is on a home ventilator. The device categories are regulatory distinct, and the post-sale support requirements (battery, backup machine, caregiver training, 24/7 service access) are meaningfully higher for home ventilation than for home NIV.
Typical devices: Philips Trilogy series, ResMed Astral, Breas Vivo series, dedicated home ventilator platforms from other manufacturers. Price range ₹3,50,000–10,00,000+ depending on configuration.
The decision tree in practice
Putting it together as a flowchart:
- Start: is there polysomnography-confirmed sleep-disordered breathing? If no, stop and evaluate further. If yes, continue.
- Is the picture primarily obstructive, without hypercapnia, without central predominance? → CPAP / APAP. Titrate, monitor, done.
- Is the picture obstructive but with pressure intolerance or mild hypoventilation? → BiPAP-S as a step up.
- Is the picture central, mixed, or a patient with neuromuscular disease or overlap syndrome without stable volumes? → BiPAP-ST.
- Is the picture any of the above with chronic hypercapnia, or is the patient failing BiPAP-ST on CO₂ metrics? → TVAPS (AVAPS / iVAPS).
- Is the patient dependent on ventilation for most of the 24-hour cycle, or requiring tracheostomy-circuit support? → Home mechanical ventilator.
- Is the patient HFrEF with LVEF ≤ 45%? → Do not prescribe ASV. Use CPAP or BiPAP-ST depending on phenotype. (See the heart failure article.)
When to escalate, when to de-escalate
Escalation is more common than de-escalation, but de-escalation does happen and should be considered:
- A bariatric surgery patient who has lost significant weight may no longer need the BiPAP-ST they were initiated on pre-surgery. A repeat sleep study at 6–12 months post-op, and de-escalation to CPAP if warranted, is appropriate.
- A patient whose heart failure is now well-controlled may see the central component of their sleep-disordered breathing resolve. A repeat study and consideration of de-escalation is warranted.
- A patient recovering from a reversible neuromuscular picture (e.g., Guillain-Barré syndrome with good recovery) may be weaned off BiPAP entirely. Ventilator weaning is a specialist process and should not be improvised.
Escalation tends to happen in:
- NMD progression — from BiPAP-S to BiPAP-ST to TVAPS to full ventilator, over the course of the disease.
- OHS with worsening ventilatory picture despite optimal CPAP — step up to TVAPS.
- Progressive COPD with incident hypercapnic exacerbations — step up from CPAP-only to home NIV.
A practical note on matching the device to the mode
A patient prescribed BiPAP-ST must have a BiPAP-ST-capable device. A patient prescribed TVAPS must have a TVAPS-capable device. This sounds obvious but is mis-sold regularly in the Indian market: a distributor with inventory of BiPAP-S devices may attempt to sell the patient “a BiPAP” without clarifying mode capability, and the device arrives without the prescribed mode available. Ask the distributor to confirm in writing that the specific model ordered supports the prescribed mode. If the model cannot, request a different model.
The incremental cost between BiPAP-S and BiPAP-ST is usually ₹20,000–40,000. The incremental cost between BiPAP-ST and TVAPS is usually ₹30,000–80,000. These are not trivial amounts for Indian families, but they are small compared to the cost of sub-therapeutic home ventilation across a lifetime of NMD or chronic hypercapnic COPD.
The bottom line
Positive-pressure therapy is a stepped family of modes, not a single intervention. The mode selection flows from the clinical picture and the physiology, not from the device inventory of a distributor or the preference of a patient. Matching the mode correctly is the single highest-yield step in producing a successful long-term therapy. Device selection matters but is secondary; within the right mode, most mid-tier and premium devices from major manufacturers perform adequately in real-world practice.
Consult your sleep physician or pulmonologist before initiating any positive-pressure therapy.
References: ATS/ERS statement on NIV; AASM clinical practice guidelines on positive-pressure therapy; SERVE-HF for ASV contraindication in HFrEF; Pickwick trial for TVAPS in OHS; individual mode-specific citations in the linked articles [CITATION].